Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database

BACKGROUND: Infliximab (IFX) has changed the management of many life-threatening immune-mediated diseases. The high cost of IFX and its patent expiry have led to pharmaceutical companies developing a biosimilar; however, its safety profile remains unknown in the real world. The purpose of this study...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Pharm Health Care Sci
Main Authors: Niinomi, Iku, Hosohata, Keiko, Mori, Yasuhiro, Yamaguchi, Yuki, Wakabayashi, Tomohito, Uchida, Mayako, Iwanaga, Kazunori
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Short Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6781388/
https://ncbi.nlm.nih.gov/pubmed/31608149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40780-019-0149-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados